You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
Applied StemCell, based in the San Francisco Bay Area, will develop and sell CRISPR-based services and reagents under a license from ERS Genomics.
The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.
An international committee finds genome editing is not yet ready to be used on human embryos.
The panel also said that if any nation does decide to allow germline genome editing, its use should be limited to preventing serious monogenic diseases.
In Science this week: 29 widespread antiviral gene cassettes uncovered, and more.
The company has taken an exclusive license to the Casɸ proteins and is working to characterize their capabilities to determine how they can best be used.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.
The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.
Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.
In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.